1. In June 2024, our team successfully published a landmark study in the Blood Pressure Journal titled 'Discovering a Novel Genetic Variant in Eleven Family Members with Isolated Pheochromocytoma Linked to Von Hippel-Lindau (VHL) Syndrome, Aligning with the Type 2C Phenotype.' This research uncovered a previously unreported genetic variant in eleven family members in Jordan, all initially diagnosed with drug-resistant hypertension. Through comprehensive genetic analysis, we identified pheochromocytoma linked to VHL syndrome as the underlying condition, specifically aligning with the Type 2C phenotype. This discovery contributes to a deeper understanding of the genetic mechanisms behind familial pheochromocytoma and hypertension, paving the way for improved diagnostics and personalized treatment strategies for hereditary endocrine disorders.

2. In February 2024, our team published a study in the Journal of Personalized Medicine titled 'The Association of M235T Genetic Polymorphism in Angiotensinogen Gene and Other Non-Genetic Factors with Essential Hypertension among Jordanian Patients.' This comprehensive research investigated the complex interplay between genetic predisposition—specifically the M235T polymorphism in the angiotensinogen (AGT) gene—and various non-genetic factors, such as lifestyle, diet, and environmental influences, in relation to the development of essential hypertension in Jordanian patients. By analyzing the combined impact of these genetic and non-genetic factors, the study provided critical insights into the multifactorial nature of hypertension and underscored the potential for personalized medicine approaches in the prevention, diagnosis, and treatment of cardiovascular diseases. The findings offer a more tailored strategy for managing hypertension, particularly within populations with similar genetic backgrounds.